Kiniksa Pharmaceuticals International PLC Class A KNSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
-
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
-
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
-
Kiniksa Pharmaceuticals Gets Orphan Drug Designation for KPL-387
Trading Information
- Previous Close Price
- $79.70
- Day Range
- $79.48–80.78
- 52-Week Range
- $35.54–83.76
- Bid/Ask
- $79.94 / $80.60
- Shares Outstanding
- 78.02M
- Market Cap
- $6.22B
- Volume/Avg
- 6,537 / 601,142
Key Statistics
- Price/Earnings (Normalized)
- 75.29
- Price/Sales
- 7.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.18%
Company Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 366
- Website
- https://www.kiniksa.com
Valuation
|
Metric
|
KNSA
|
|---|---|
Price/Earnings (Normalized) | 75.29 |
Price/Book Value | 9.50 |
Price/Sales | 7.77 |
Price/Cash Flow | 45.38 |
Price/Earnings
KNSA
Financial Strength
|
Metric
|
KNSA
|
|---|---|
Quick Ratio | 3.21 |
Current Ratio | 3.90 |
Interest Coverage | — |
Quick Ratio
KNSA
Profitability
|
Metric
|
KNSA
|
|---|---|
Return on Assets (Normalized) | 14.29% |
Return on Equity (Normalized) | 19.29% |
Return on Invested Capital (Normalized) | 18.98% |
Return on Assets
KNSA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|^>>Hl$n | LOCK|KDmgs | $69B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|&vcDFC%< | LOCK|fLC< | $47B | |||
| Haleon PLC ADR
HLN
| LOCK|!^!@N#v | LOCK|lg | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|^bhfF@t | LOCK|WX> | $33B | |||
| Viatris Inc
VTRS
| LOCK|#vcXPj | LOCK|&Q | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|@m< | LOCK|V>c | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|B^%&PJ$ | LOCK|fv | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|@&#&??% | LOCK|Q^^ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|?c!Q>V | LOCK|G%rH | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|!$$%Lv | LOCK|!!x | $2B |
United States